Press Release

31 January 2022

First *Evusheld* doses arrive in Egypt

AstraZeneca's long-acting antibody combination provides pre-exposure protection from COVID-19

A first batch of 15,000 doses of *Evusheld* (tixagevimab co-packaged with cilgavimab), AstraZeneca's long-acting antibody combination which provides pre-exposure protection from COVID-19, arrived at Cairo international airport on Saturday (29 January).

Egypt is the first African country and the fourth globally to receive *Evusheld*. The doses arrived within days of obtaining Emergency Use Authorization from the Egyptian Drug Authority (EDA), and further deliveries are expected in the coming weeks as part of a total supply of 50,000 doses in 2022.

On 16 January, the EDA granted emergency use authorization for *Evusheld* for pre-exposure prevention of COVID-19 in adults and adolescents (aged 12 and older who weigh 40kg or more) with moderate to severe immune compromise due to a medical condition or immunosuppressive medications and who may not mount an adequate immune response to COVID-19 vaccination.

Dr. Hossam Abdel Ghaffar, the official spokesperson of the Ministry of Health and Population said: "Under the guidance of our leadership, Egypt has become one of the first countries in the world to receive *Evusheld*, a breakthrough medication to protect the most vulnerable groups. The collaboration between the Ministry of Health and Population and AstraZeneca played a key role in our efforts to respond to the pandemic through the provision of the *AstraZeneca COVID-19 vaccine*. With *Evusheld*, we now have better capabilities to protect immunocompromised patients in Egypt."

Hatem Werdany, Country President for Egypt, AstraZeneca said: "We are delighted to see the first doses of *Evusheld* arrive in Egypt, soon after being granted Emergency Use Authorization by the Egyptian Drug Authority. AstraZeneca remains committed to supporting the Ministry of Health's efforts in fighting Covid-19 by bringing innovative medicines and breakthrough solutions to the Egyptian people."

About 2% of the global population is considered at increased risk of an inadequate response to a COVID-19 vaccine.1-2 This includes people with blood cancers or other cancers being treated with chemotherapy, patients on dialysis, those taking medications after an organ transplant or who are taking immunosuppressive drugs for conditions including multiple sclerosis and rheumatoid arthritis. Recent emerging evidence indicates that protecting these vulnerable

populations from getting COVID-19 could help prevent viral evolution that is an important factor in the emergence of variants.

-Ends -

Download b-roll:

https://www.dropbox.com/s/h7way3adidf2ux8/MNR_COVID_B-ROLL.mp4?dl=0

Notes

Evusheld

Evusheld, formerly known as AZD7442, is a combination of two LAABs - tixagevimab (AZD8895) and cilgavimab (AZD1061) - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus.

In December 2021, the FDA issued an EUA for the use of *Evusheld* for the pre-exposure prophylaxis (prevention) of COVID-19 in adults and adolescents (aged 12 and older who weigh 40kg or more) with moderate to severe immune compromise due to a medical condition or immunosuppressive medications and who may not mount an adequate immune response to COVID-19 vaccination, as well as those individuals for whom COVID-19 vaccination is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine. *Evusheld* is the only antibody therapy authorised in the US to prevent COVID-19 symptoms before virus exposure. *Evusheld* is also authorised for emergency use for prevention of COVID-19 in several other countries.

Recent live and pseudovirus studies from the US Food and Drug Administration, University College Oxford, UK and Washington University School of Medicine, St. Louis, US showed that *Evusheld* retains neutralising activity against the Omicron variant (B.1.1.529) and all tested SARS-CoV-2 variants of concern to date.[4-7] By combining two particularly potent antibodies with different and complementary activities against the virus, *Evusheld* was designed to evade potential resistance with the emergence of new SARS-CoV-2 variants.

Evusheld is being developed with support from the US government, including federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, under Contract No. W911QY-21-9-0001.

Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein8 and were optimized by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. The half-life extension more than triples the durability of its action compared to conventional antibodies and could afford up to 12 months of protection from COVID-19 following a single administration;9-11 data from the Phase III PROVENT trial show protection lasting at least six months.12 The reduced Fc receptor binding aims to minimize the risk of antibody-dependent enhancement of disease - a phenomenon in which virus-specific antibodies promote, rather than inhibit, infection and/or disease.13 Evusheld is delivered as an intramuscular dose of 150mg tixagevimab and 150mg cilgavimab administered in two separate, consecutive injections.

Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here.

For media queries, please contact: Mona.moneim@HKstrategies.com / D: +202 358 8326

M: +201010045595

References

1. Harpaz R, et al. Prevalence of immunosuppression among US adults, 2013. JAMA. 2016 Dec 20;316(23):2547-2548. Available at: https://doi.org/10.1001/jama.2016.16477

2. AstraZeneca data on file.

3. Corey L, et al. SARS-CoV-2 Variants in Patients with Immunosuppression. N Engl J Med 2021; 385:562-566. DOI: 10.1056/NEJMsb2104756.

4. Dejnirattisai W, et al. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. bioRxiv. 2021; doi: 10.1101/2021.12.03.471045.

5. VanBlargan LA, et al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. bioRxiv. 2021; doi: 10.1101/2021.12.15.472828.

6. National Institutes of Health. National Center for Advancing Translational Sciences Open Data Portal. SARS-CoV-2 Variants & Therapeutics. AZD7442 (AZD8895 and AZD1061; mAbs for SARS-CoV-2) Omicron Antiviral Resistance Information. Available at: https://opendata.ncats.nih.gov/variant/datasets?id=160 [Last accessed January 2022].

7. National Institutes of Health. National Center for Advancing Translational Sciences Open Data Portal. SARS-CoV-2 Variants & Therapeutics, All Variants Reported in vitro Therapeutic Activity. Available at: https://opendata.ncats.nih.gov/variant/activity. [Last accessed: January 2022].

8. Dong J, et al. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. bioRxiv. 2021; doi: 10.1101/2021.01.27.428529.

9. Robbie GJ, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother. 2013; 57 (12): 6147-53.

10. Griffin MP, et al. Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. Antimicrob Agents Chemother. 2017; 61(3): e01714-16.

11. Domachowske JB, et al. Safety, tolerability and pharmacokinetics of MEDI8897, an extended half-life single-dose respiratory syncytial virus prefusion F-targeting monoclonal antibody administered as a single dose to healthy preterm infants. Pediatr Infect Dis J. 2018; 37(9): 886-892.
12. AstraZeneca news release. New analyses of two AZD7442 COVID-19 trials in high-risk populations confirm robust efficacy and long-term prevention. Available at: https://www.astrazeneca.com/media-centre/press-releases/2021/new-analyses-of-two-azd7442-covid-19-phase-iii-trials-in-high-risk-populations-confirm-robust-efficacy-and-long-term-prevention.html. [Last accessed: January 2022].
13. van Erp EA, et al. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019; 10: 548.